Dawson James Securities Reiterates Market Outperform Rating, $4 PT on Keryx Biopharmaceuticals
In a report published Wednesday, Dawson James Securities reiterated its Market Outperform rating and $4.00 price target on Keryx Biopharmaceuticals (NASDAQ: KERX).
Dawson James Securities noted, “We maintain our Market Outperform rating and $4 price target on KERX shares. We derive our $4 price target by the synthesis of our DCF valuation ($3.73), comparables analysis (~$5.00), and our standardized CAGR methodology ($5.77). Risks to our valuation included clinical and regulatory, partnering, competitive, reimbursement, intellectual property and financial.”
Keryx Biopharmaceuticals closed on Tuesday at $2.93.
Latest Ratings for KERX
|Nov 2016||Maxim Group||Upgrades||Hold||Buy|
|Aug 2016||Brean Capital||Downgrades||Buy||Hold|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.